U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30O5
Molecular Weight 362.4607
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCORTISONE

SMILES

C[C@@]12CCC(=O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@](C(=O)CO)([C@@]4(C)C[C@@]([H])([C@@]31[H])O)O

InChI

InChIKey=JYGXADMDTFJGBT-VWUMJDOOSA-N
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H30O5
Molecular Weight 362.4607
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008697s032_33lbl.pdf

Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). Hydrocortisone is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

CNS Activity

Curator's Comment:: shown in dogs

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Palliative
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Primary
Cortef

Approved Use

CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Launch Date

-538012800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
258 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1162 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.82 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCORTISONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9.9%
HYDROCORTISONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 4 times / day multiple, intramuscular
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
200 mg 4 times / day multiple, intravenous
Highest studied dose
Dose: 200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
200 mg 4 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
200 mg single, intravenous
Highest studied dose
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
unhealthy, 56 years (tange: 40-64 years)
Health Status: unhealthy
Age Group: 56 years (tange: 40-64 years)
Sex: M+F
Sources:
2.5 % 4 times / day multiple, topical
Dose: 2.5 %, 4 times / day
Route: topical
Route: multiple
Dose: 2.5 %, 4 times / day
Sources:
unhealthy, adult
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Other AEs: Infection...
Other AEs:
Infection (below serious, 6 patients)
Sources:
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
Other AEs: Hyperbilirubinemia, Hypertension...
Other AEs:
Hyperbilirubinemia (serious, 1 patient)
Hypertension (serious, 1 patient)
Adrenal insufficiency (serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Infection below serious, 6 patients
1 mg/kg 4 times / day multiple, intravenous
Dose: 1 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg/kg, 4 times / day
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Adrenal insufficiency serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
Hyperbilirubinemia serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
Hypertension serious, 1 patient
0.5 mg/kg 4 times / day multiple, intravenous
Dose: 0.5 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.5 mg/kg, 4 times / day
Sources:
unhealthy, neonate
Health Status: unhealthy
Age Group: neonate
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Endocrine and metabolic effects of insulin sensitizers in the treatment of patients with polycystic ovary syndrome and hyperinsulinaemia.
2001
Individual differences in the diurnal cycle of salivary free cortisol: a replication of flattened cycles for some individuals.
2001 Apr
Circulatory support of the sick preterm infant.
2001 Feb
Interactions among paternal behavior, steroid hormones, and parental experience in male marmosets (Callithrix kuhlii).
2001 Feb
Menstrual cycle variation in spatial ability: relation to salivary cortisol levels.
2001 Feb
Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
2001 Feb
Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching.
2001 Feb
Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3',5'-monophosphate and p53 activation in immortalized human granulosa cells: involvement of Bcl-2.
2001 Feb
Regulation of phosphate uptake in primary cultured rabbit renal proximal tubule cells by glucocorticoids: evidence for nongenomic as well as genomic mechanisms.
2001 Feb
Plasma adrenocorticotropin and cortisol concentrations during acute hypoxemia after a reversible period of adverse intrauterine conditions in the ovine fetus during late gestation.
2001 Feb
The effects of epidural block on the distribution of lymphocyte subsets and natural-killer cell activity in patients with and without pain.
2001 Feb
Pulsatile growth hormone secretion decreases S-adenosylmethionine synthetase in rat liver.
2001 Feb
PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells.
2001 Feb
Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2'-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke.
2001 Feb
Postnatal glucocorticoids in very preterm infants: "the good, the bad, and the ugly"?
2001 Feb
Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/enhancer-binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor.
2001 Feb
Metabolic abnormalities in patients with adrenal incidentaloma.
2001 Feb
Is hydrocortisone clearance 50% slower in the evening than in the morning?
2001 Feb
Paraneoplastic hypercortisolism as a risk factor for severe infections in patients with malignant diseases.
2001 Feb
Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth.
2001 Feb
Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade.
2001 Feb
Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report.
2001 Feb
Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.
2001 Feb
Oral glucose augments the counterregulatory hormone response during insulin-induced hypoglycemia in humans.
2001 Feb
The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis.
2001 Feb
Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies.
2001 Feb
Human glucocorticoid feedback inhibition is reduced in older individuals: evening study.
2001 Feb
Troglitazone amplifies counterregulatory responses to hypoglycemia in nondiabetic subjects.
2001 Feb
Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.
2001 Feb
Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia.
2001 Feb
Electrophysiological effects of corticosteroids on the retinal pigment epithelium.
2001 Feb
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
2001 Feb
Green fluorescent protein mutant as label in homogeneous assays for biomolecules.
2001 Feb 1
Carbachol induces homologous steroidogenic refractoriness of bovine fasciculata-reticularis cells.
2001 Feb 14
Post-dexamethasone cortisol level and memory performance in elderly depressed patients.
2001 Feb 2
Inhibition of cortisol secretion in dispersed head kidney cells of rainbow trout (Oncorhynchus mykiss) by endosulfan, an organochlorine pesticide.
2001 Jan
Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways.
2001 Jan
Tixocortol pivalate contact allergy in the GPMT: frequency and cross-reactivity.
2001 Jan
Serum allopregnanolone in women with postpartum "blues".
2001 Jan
Net amino acid flux across the fetal liver and placenta during spontaneous ovine parturition.
2001 Jan
Growth hormone deficiency caused by pituitary stalk interruption in Fanconi's anemia.
2001 Jan
Back to basics: early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia.
2001 Jan
Serum thyrotropin concentrations and bioactivity during sleep deprivation in depression.
2001 Jan
Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice.
2001 Jan
Localization and developmental regulation of 11beta-hydroxysteroid dehydrogenase-1 and -2 in the baboon syncytiotrophoblast.
2001 Jan
Circadian variation in O6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects.
2001 Jan 1
A population physiologically based pharmacokinetic/pharmacodynamic model for the inhibition of 11-beta-hydroxysteroid dehydrogenase activity by glycyrrhetic acid.
2001 Jan 1
Monohydroxylation and esterification as determinants of the effects of cis- and trans-9-octadecenoic acids on the permeation of hydrocortisone and 5-fluorouracil across hairless mouse skin in vitro.
2001 Jan 16
The use of chitosan gels as matrices for electrically-modulated drug delivery.
2001 Jan 29
Fetal hypothalamus-pituitary-adrenal axis on the road to parturition.
2001 Jan-Feb
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Many Hydrocortisone products are used topically https://www.drugs.com/pro/hydrocortisone.html
The initial dosage of CORTEF (Hydrocortisone) Tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated.
Route of Administration: Oral
Hydrocortisone concentration-dependently inhibited the current induced by 3 x 10(-5) M ACh with a half maximum inhibitory concentration (IC50) of 2.1 x 10(-4) M (in rats).
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:49:03 UTC 2021
Edited
by admin
on Fri Jun 25 20:49:03 UTC 2021
Record UNII
WI4X0X7BPJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCORTISONE
EP   GREEN BOOK   HSDB   II   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
HYDROCORTISONE [ORANGE BOOK]
Common Name English
HYDROCORTISONE [WHO-IP]
Common Name English
HYDROCORTISONE ACETATE IMPURITY A [EP]
Common Name English
HYDROCORTISONE COMPONENT OF CALMURID HC
Common Name English
HYDROCORTISONE HYDROGEN SUCCINATE IMPURITY A [EP]
Common Name English
PREDNISOLONE IMPURITY A [EP]
Common Name English
HYDROCORTISONE [USP-RS]
Common Name English
PROCTOCORT
Brand Name English
ANUSOL HC
Brand Name English
GLYCORT
Brand Name English
HYDROCORTISONE COMPONENT OF PYOCIDIN
Common Name English
CORTENEMA
Brand Name English
HYDROCORTISONE [II]
Common Name English
OTOCORT COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE COMPONENT OF OTOBIOTIC
Common Name English
HYDROCORTISONE SODIUM SUCCINATE IMPURITY A [EP]
Common Name English
TEXACORT
Brand Name English
PLENADREN
Brand Name English
HYDROCORTISONE COMPONENT OF OTICAIR
Common Name English
CORTEF
Brand Name English
HYDROCORTISONE [VANDF]
Common Name English
CORTISOL
Common Name English
AEROSEB-HC
Brand Name English
PREGN-4-ENE-3,20-DIONE, 11,17,21-TRIHYDROXY-, (11.BETA.)-
Systematic Name English
NOGENIC HC
Brand Name English
HYDROCORTISONE [MART.]
Common Name English
STIE-CORT
Brand Name English
EPICORT
Brand Name English
OTOBIONE COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE [USP MONOGRAPH]
Common Name English
HYDROCORTISONE [MI]
Common Name English
HYDROCORTONE
Brand Name English
HYDROCORTISONE [GREEN BOOK]
Common Name English
COLOCORT
Brand Name English
HYDROCORTISONE COMPONENT OF OTOBIONE
Common Name English
PEDIOTIC COMPONENT HYDROCORTISONE
Common Name English
CALMURID HC COMPONENT HYDROCORTISONE
Common Name English
SYNACORT
Brand Name English
NSC-10483
Code English
CORTRIL
Brand Name English
FLEXICORT
Code English
PYOCIDIN COMPONENT HYDROCORTISONE
Common Name English
BETA-HC
Brand Name English
ORLEX HC COMPONENT HYDROCORTISONE
Common Name English
ACETASOL HC COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE COMPONENT OF ACETASOL HC
Common Name English
VOSOL HC COMPONENT HYDROCORTISONE
Common Name English
CETACORT
Brand Name English
CORT-DOME
Brand Name English
DERMACORT
Brand Name English
HYDROCORTISONUM [WHO-IP LATIN]
Common Name English
BALNEOL-HC
Brand Name English
OTICAIR COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE COMPONENT OF ORLEX HC
Common Name English
CIPRO HC COMPONENT HYDROCORTISONE
Common Name English
HYDROCORTISONE COMPONENT OF OTOCORT
Common Name English
HYDROCORTISONE [INN]
Common Name English
HYDROCORTISONE COMPONENT OF VOSOL HC
Common Name English
NUTRACORT
Brand Name English
ACTICORT
Brand Name English
PENECORT
Brand Name English
HYDROCORTISONE [HSDB]
Common Name English
HYDROCORTISONE COMPONENT OF PEDIOTIC
Common Name English
HYDROCORTISONE [EP MONOGRAPH]
Common Name English
ELDECORT
Brand Name English
HYTONE
Brand Name English
ALA-SCALP
Brand Name English
HYDROCORTISONE COMPONENT OF ALPHADERM
Common Name English
ALPHADERM COMPONENT HYDROCORTISONE
Common Name English
11.BETA.,17,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE
Systematic Name English
HYDROCORTISONE [WHO-DD]
Common Name English
ALKINDI SPRINKLE
Brand Name English
ALA-CORT
Brand Name English
HYDROCORTISONE COMPONENT OF CIPRO HC
Common Name English
OTOBIOTIC COMPONENT HYDROCORTISONE
Common Name English
Classification Tree Code System Code
LIVERTOX 485
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC S01CB03
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QA01AC03
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 53346-3
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC S02CA03
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QS01CA03
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QS03CA04
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
CFR 21 CFR 524.1662A
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 18.1
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QR01AD60
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC S01CA03
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
FDA ORPHAN DRUG 234906
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 2144-4
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
EMA ASSESSMENT REPORTS PLENADREN (AUTHORIZED: ADRENAL INSUFFICIENCY)
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC S03CA04
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 44310-1
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 35202-1
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 78988-3
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 14675-3
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QD07AA02
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QS02BA01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 32310-5
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
EU-Orphan Drug EU/3/06/372
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QS02CA03
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC D07AA02
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QA07EA02
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
CFR 21 CFR 524.1484D
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QH02AB09
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 26828-4
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 51844-9
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QC05AA01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC A01AC03
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
FDA ORPHAN DRUG 487515
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QS01BB01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
CFR 21 CFR 524.1132
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 15043-3
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC R01AD60
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 03
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QD07XA01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 53337-2
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QD07BA04
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
CFR 21 CFR 524.1484I
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
EPA PESTICIDE CODE 6312
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
NDF-RT N0000175450
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QS01BA02
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC S01BB01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 83089-3
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
CFR 21 CFR 524.1484H
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
FDA ORPHAN DRUG 467014
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 53336-4
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 83090-1
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC D07BA04
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 28550-2
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC D07CA01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 83088-5
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 50848-1
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC H02AB09
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 33257-7
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 2142-8
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 11155-9
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC S02BA01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QD07CA01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC A07EA02
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 76352-4
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC C05AA01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 17.3
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 20622-7
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 13.3
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 50336-7
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 53345-5
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC S01BA02
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-ATC D07XA01
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
WHO-VATC QS01CB03
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
FDA ORPHAN DRUG 716719
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 83091-9
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
CFR 21 CFR 524.1204
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 14158-0
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 45184-9
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
NCI_THESAURUS C2323
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 76347-4
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
CFR 21 CFR 524.155
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
FDA ORPHAN DRUG 441614
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
LOINC 2143-6
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
Code System Code Type Description
RXCUI
5492
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY RxNorm
USP_CATALOG
1316004
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY USP-RS
INN
38
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
LACTMED
Hydrocortisone
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
LACTMED
Hydrocortisone, Topical
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
DRUG BANK
DB00741
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
PUBCHEM
5754
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
FDA UNII
WI4X0X7BPJ
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
WIKIPEDIA
CORTISOL
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
IUPHAR
2868
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
CAS
50-23-7
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
EVMPD
SUB08065MIG
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
MERCK INDEX
M6094
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
1388
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
ChEMBL
CHEMBL389621
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
NCI_THESAURUS
C555
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
HYDROCORTISONE
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Very slightly soluble in water and ether R; sparingly soluble in ethanol (~750 g/l) TS and acetone R. Category: Adrenocortical steroid. Storage: Hydrocortisone should be kept in a well-closed container, protected from light. Additional information: Hydrocortisone melts at about 214?C with decomposition. Definition: Hydrocortisone contains not less than 97.0% and not more than 102.0% of C21H30O5, calculated with reference to the dried substance.
HSDB
3339
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
EPA CompTox
50-23-7
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-020-1
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
MESH
D006854
Created by admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
2.4 FOLD INDUCTION OF GR MMTV-liciferase reporter gene
AGONIST
FOLD INDUCTION
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TARGET -> AGONIST
2.4 FOLD INDUCTION OF GR MMTV-luciferase reporter gene
AGONIST
FOLD INDUCTION
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
PARENT -> METABOLITE ACTIVE
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
correction factor: for the calculation of content, multiply the peak area of impurity E by 2.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
correction factor: for the calculation of content, multiply the peak area of impurity D by 1.8
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY